HomeAI · summaries
Storia in 3 fonti
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for this cancer can lead to significant lifelong side effects. Jemperli's safety profile remains consistent with prior studies in solid tumors. GSK anticipates Jemperli will significantly contribute to its long-term sales targets.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for…
- ·
benzinga.com
What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)
GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.
- ·
fiercepharma.com
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the company’s Jemperli has met the main goal of a phase 2…